Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13788599 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL1536845 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL165641 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL16134189 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL1766170 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL16134190 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL1766162 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL1766172 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL22771166 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL17776284 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042084-A1 | SORBENTS FUNCTIONALIZED WITH LIGANDS HAVING AN AMINOSILICONE FUNCTIONAL GROUP | GENERAL ELECTRIC TECHNOLOGY GMBH (CH) | 2026-02-12 | — | — | US | claimed |
| EP-4556112-A2 | SORBENT COMPOSITIONS, SYSTEMS, AND METHODS | General Electric Technology GmbH (CH) | 2025-05-21 | — | — | EP | claimed |
| US-12263464-B2 | Method for in-situ synthesis of metal organic frameworks (MOFs), covalent organic frameworks (COFs) and zeolite imidazolate frameworks (ZIFs), and applications thereof | DESICCANT ROTORS INTERNATIONAL PRIVATE LIMITED (IN) | 2025-04-01 | — | — | US | claimed |
| US-20240199653-A1 | METHOD FOR FORMING AN ELECTRICALLY CONDUCTIVE METAL ORGANIC FRAMEWORK COMPOSITE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2024-06-20 | — | — | US | claimed |
| WO-2024123903-A1 | SORBENT COMPOSITIONS, SYSTEMS, AND METHODS | GE INFRASTRUCTURE TECHNOLOGY LLC (US) | 2024-06-13 | — | — | WO | claimed |
| US-11466400-B2 | Finish composition | HEXCEL CORPORATION (US) | 2022-10-11 | — | — | US | claimed |
| EP-3810836-A1 | FINISH COMPOSITION | Hexcel Corporation (US) | 2021-04-28 | — | — | EP | claimed |
| EP-3801880-A1 | METHOD FOR IN-SITU SYNTHESIS OF METAL ORGANIC FRAMEWORKS (MOFS), COVALENT ORGANIC FRAMEWORKS (COFS) AND ZEOLITE IMIDAZOLATE FRAMEWORKS (ZIFS), AND APPLICATIONS THEREOF | Desiccant Rotors International Private Ltd. (IN) | 2021-04-14 | — | — | EP | claimed |
| US-20210016245-A1 | METHOD FOR IN-SITU SYNTHESIS OF METAL ORGANIC FRAMEWORKS (MOFs), COVALENT ORGANIC FRAMEWORKS (COFs) AND ZEOLITE IMIDAZOLATE FRAMEWORKS (ZIFs), AND APPLICATIONS THEREOF | DESICCANT ROTORS INTERNATIONAL PRIVATE LIMITED (IN) | 2021-01-21 | — | — | US | claimed |
| US-20200291045-A1 | CONDUCTIVITY ENHANCEMENT OF MOFS VIA DEVELOPMENT OF MOFPOLYMER COMPOSITE MATERIAL | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2020-09-17 | — | — | US | claimed |
| EP-2739169-B1 | POROUS CATALYTIC MATRICES FOR ELIMINATION OF TOXICANTS FOUND IN TOBACCO COMBUSTION PRODUCTS | MASSACHUSETTS INST TECHNOLOGY (US) | 2019-06-12 | — | — | EP | claimed |
| US-20160208298-A1 | ENZYMATIC PROCESS FOR THE REGIOSELECTIVE MANUFACTURING OF N-FMOC-DOXORUBICIN-14-O-DICARBOXYLIC ACID MONO ESTERS | AETERNA ZENTARIS GMBH (DE) | 2016-07-21 | — | — | US | claimed |
| EP-3045540-A1 | Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters | Æterna Zentaris GmbH (DE) | 2016-07-20 | — | — | EP | claimed |
| US-20140311507-A1 | Porous Catalytic Matrices for Elimination of Toxicants Found in Tobacco Combustion Products | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-23 | — | — | US | claimed |
| EP-2739169-A2 | POROUS CATALYTIC MATRICES FOR ELIMINATION OF TOXICANTS FOUND IN TOBACCO COMBUSTION PRODUCTS | Massachusetts Institute Of Technology (US) | 2014-06-11 | — | — | EP | claimed |
| WO-2013019865-A2 | POROUS CATALYTIC MATRICES FOR ELIMINATION OF TOXICANTS FOUND IN TOBACCO COMBUSTION PRODUCTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-02-07 | — | — | WO | claimed |
| US-6342300-B1 | POLYESTERS | CELANESE VENTURES GMBH (DE) | 2002-01-29 | — | — | US | claimed |
| US-5017675-A | Flexibility | HOECHST AG (DE) | 1991-05-21 | — | — | US | claimed |
| US-20260138938-A1 | SEPARATION METHOD | DAIKIN INDUSTRIES, LTD. (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-0027942-A1 | Sizing composition for glass fibres, glass fibres sized therewith and process for their preparation, as well as glass fibre composites | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042084-A1 | SORBENTS FUNCTIONALIZED WITH LIGANDS HAVING AN AMINOSILICONE FUNCTIONAL GROUP | SRMS, TYRO3, SELE | LMNA 2914/4885EGLN1 4388/4885ALKBH5 1279/4885 |
| US-20260138938-A1 | SEPARATION METHOD | DCX, FGB, TPR | LMNA 1455/4885EGLN1 4772/4885ALKBH5 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.